Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (18+ years) recipients of kidney or kidney/pancreas transplants~* Willing to sign an IRB (institutional review board)-approved consent and to comply with study requirements~* DSA (donor specific antibodies) detected by SAB (single antigen beads) screening with MFI ≥ 2000~* Graft biopsy performed within prior 30 days~* Stable renal function defined by serum creatinine increase ≤ 30% over prior 6 months~* Subacute antibody-mediated rejection on biopsy defined by ptc + g + C4d ≥ 2 by Banff 2013 criteria~Exclusion Criteria:~* Kidney/liver or kidney/heart recipient~* Unwilling/unable to undergo screening biopsy~* HIV (human immunodeficiency virus), HCV (hepatitis-C virus), or HBsAg (hepatitis-B surface antigen) positive~* Active/untreated infection~* Acute cellular rejection with Banff grade 1b, 2a, 2b on initial biopsy requiring rATG (rabbit anti-thymocyte globulin) therapy~* Pregnant or nursing females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 - conversion to Envarsus XR (Type: ACTIVE_COMPARATOR): Optimize: conversion to Envarsus XR (Tacrolimus Extended Release Oral Tablet \[Envarsus\]) with goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol
- Arm 2 - plasma exchange and IVIG (Type: ACTIVE_COMPARATOR): Treat clinical AMR: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).